REGISTERED NUMBER: |
Financial Statements |
For The Year Ended 31 January 2024 |
for |
EIMAN PHARMA LIMITED |
REGISTERED NUMBER: |
Financial Statements |
For The Year Ended 31 January 2024 |
for |
EIMAN PHARMA LIMITED |
EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506) |
Contents of the Financial Statements |
For The Year Ended 31 January 2024 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 4 |
EIMAN PHARMA LIMITED |
Company Information |
For The Year Ended 31 January 2024 |
DIRECTORS: |
SECRETARY: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
Accountants & Tax Advisers |
79 College Road |
Harrow |
Middlesex |
HA1 1BD |
EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506) |
Balance Sheet |
31 January 2024 |
31.1.24 | 31.1.23 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
Investments | 5 |
CURRENT ASSETS |
Debtors | 6 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 7 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
CAPITAL AND RESERVES |
Called up share capital | 8 |
Retained earnings |
SHAREHOLDERS' FUNDS |
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506) |
Balance Sheet - continued |
31 January 2024 |
The financial statements were approved by the Board of Directors and authorised for issue on |
EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506) |
Notes to the Financial Statements |
For The Year Ended 31 January 2024 |
1. | STATUTORY INFORMATION |
EIMAN PHARMA LIMITED is a |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Tangible fixed assets |
Investments in associates |
Investments in associate undertakings are recognised at cost. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was |
EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506) |
Notes to the Financial Statements - continued |
For The Year Ended 31 January 2024 |
4. | TANGIBLE FIXED ASSETS |
Plant and |
machinery |
etc |
£ |
COST |
Additions |
At 31 January 2024 |
DEPRECIATION |
Charge for year |
At 31 January 2024 |
NET BOOK VALUE |
At 31 January 2024 |
5. | FIXED ASSET INVESTMENTS |
Interest |
in |
associate |
£ |
COST |
At 1 February 2023 | 60 |
Disposals | ( |
) |
At 31 January 2024 |
NET BOOK VALUE |
At 31 January 2024 |
At 31 January 2023 |
On 6th November 2023,the following disposals took place: |
15 Ordinary shares in Liqmeds Lifecare Limited were sold for an upfront consideration of £185,200.85 and a further ascertainable deferred consideration of £548,800 receivable on an earn out basis over 3 years from date of completion. |
15 Ordinary shares in Liqmeds Worldwide Limited were sold for an upfront consideration of £4,365,448.51 and a further ascertainable deferred consideration of £12,936,000 receivable on an earn out basis over 3 years from date of completion. |
30 Ordinary shares in Medsolutions (Europe) Limited were sold for an upfront consideration of £170,082.41 and a further ascertainable deferred consideration of £504,000 receivable on an earn out basis over 3 years from date of completion. |
EIMAN PHARMA LIMITED (REGISTERED NUMBER: 09685506) |
Notes to the Financial Statements - continued |
For The Year Ended 31 January 2024 |
6. | DEBTORS |
31.1.24 | 31.1.23 |
£ | £ |
Amounts falling due within one year: |
Other debtors |
Amounts falling due after more than one year: |
Other debtors |
Aggregate amounts |
Other debtors balance due within 1 year includes £200,000 loaned to Eiman Investments Limited, £25,000 to Wave Pharma Regulatory Ltd, £700,000 to Everest Pharma Ltd, £300,010 to P Singh & £25,000 to S Juttla. |
Other Debtors balance of amounts due more than 1year refers to an amount of £13,988,800 of ascertainable deferred consideration to be received on an earn out basis over 3 years.. |
7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
31.1.24 | 31.1.23 |
£ | £ |
Other creditors |
Other creditors includes £100,500 due to Wave Pharma Limited. |
8. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal | 31.1.24 | 31.1.23 |
value: | £ | £ |
Ordinary | 1 | 400 | 200 |
Full details of shareholders are as follows: |
136 Ordinary shares held by Mohammad Arsalaan Khan |
132 Ordinary shares held by Romana Khan |
132 Ordinary shares held by Maaira Khan |